查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620441

2024 - 2032 年院內感染治療市場機會、成長動力、產業趨勢分析與預測

Hospital Acquired Infections Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球院內感染治療市場估值為126 億美元，預計2024 年至2032 年複合年成長率為3.2%。相關感染的日益關注所推動。由於多種因素，醫院感染的盛行率正在上升，包括住院人數增加、患者住院時間延長以及侵入性醫療設備的使用不斷增加。泌尿道感染、肺炎和血液感染等常見感染增加了對有效治療解決方案的需求。此外，免疫功能低下患者數量的不斷增加進一步增加了對這些感染的易感性。

依藥物類型分類，市場分為抗菌藥物、抗病毒藥物、抗真菌藥物和其他藥物。 2023年，抗菌藥物以92億美元的收入佔據市場主導地位。這些藥物對於治療 HAI 至關重要，尤其是在醫療環境中抗生素抗藥性細菌不斷增加的情況下。抗菌藥物對於解決 MRSA 和艱難梭菌等抗藥性菌株引起的感染至關重要，這些感染需要有效的治療干預措施。

就給藥途徑而言，市場分為靜脈注射（IV）、口服、局部和吸入療法。靜脈注射細分市場處於領先地位，到 2023 年將產生 57 億美元的收入。這對於管理嚴重感染尤其重要，因為需要採取快速治療行動來對抗危及生命的情況。靜脈注射藥物的高效性和立竿見影的效果使其成為治療危重 HAI 病例的首選。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 126 億美元
預測值 164 億美元
複合年成長率 3.2%

2023 年北美市場規模達 47 億美元，預計 2024 年至 2032 年複合年成長率為 2.5%。北美龐大的醫院和醫療機構網路增加了醫院感染的風險，因此感染控制措施至關重要。領先製藥公司的存在以及持續的研發工作也有助於先進治療方案的開發和可用性，進一步推動市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 院內感染發生率上升
      • 醫療技術和藥物開發的進步
      • 越來越關注病人安全和優質護理
    • 產業陷阱與挑戰
      • 缺乏患者意識和診斷
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 報銷場景
  • 波特的分析
  • PESTEL分析
  • 管道分析
  • 未來市場趨勢
  • 差距分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 抗菌藥物
  • 抗病毒藥物
  • 抗真菌藥物
  • 其他藥物種類

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 靜脈注射 (IV)
  • 口服
  • 專題
  • 吸入

第 7 章：市場估計與預測：按感染類型，2021 - 2032

  • 主要趨勢
  • 手術部位感染
  • 血流感染
  • 泌尿道感染
  • 呼吸器相關性肺炎
  • 其他醫院感染

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • Abbott
  • AbbVie
  • Allergan
  • Eugia Pharma
  • Bayer
  • DAIICHI SANKYO COMPANY
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • GSK
  • Hikma Pharmaceuticals
  • Melinta Therapeutics
  • Merck & Co
  • Pfizer
  • Sanofi
  • Viatris
簡介目錄
Product Code: 11913

The Global Hospital Acquired Infections Therapeutics Market was valued at USD 12.6 billion in 2023 and is expected to grow at a CAGR of 3.2% from 2024 to 2032. This growth is largely driven by the rising incidence of healthcare-associated infections, the increasing focus on improved patient care, and active government efforts to control the spread of HAIs. The prevalence of HAIs is climbing due to several factors, including higher hospital admissions, extended patient stays, and the growing use of invasive medical devices. Common infections such as urinary tract infections, pneumonia, and bloodstream infections are contributing to the demand for effective therapeutic solutions. Additionally, the growing population of immunocompromised patients further increases the susceptibility to these infections.

By drug type, the market is segmented into antibacterial, antiviral, antifungal, and other drugs. In 2023, antibacterial drugs dominated the market with a revenue of USD 9.2 billion. These drugs are essential for treating HAIs, especially with the increasing presence of antibiotic-resistant bacteria in healthcare environments. Antibacterial drugs are critical in addressing infections caused by resistant strains like MRSA and Clostridium difficile, which require potent therapeutic interventions.

In terms of administration routes, the market is divided into intravenous (IV), oral, topical, and inhalation therapies. The IV segment led the market, generating USD 5.7 billion in 2023. IV administration is the preferred method in hospital settings, as it ensures the rapid delivery of medications directly into the bloodstream. This is particularly important for managing severe infections, where quick therapeutic action is needed to combat life-threatening conditions. The high efficacy and immediate impact of IV-administered drugs make it the go-to option for managing critical HAI cases.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$12.6 Billion
Forecast Value$16.4 Billion
CAGR3.2%

The North American market accounted for USD 4.7 billion in 2023 and is expected to grow at a CAGR of 2.5% between 2024 and 2032. The demand for HAI therapeutics in the region is driven by the high rate of infections and the presence of an advanced healthcare system. North America's vast network of hospitals and healthcare facilities increases the risk of HAIs, making infection control measures essential. The presence of leading pharmaceutical companies and ongoing research and development efforts also contribute to the development and availability of advanced treatment options, further fueling market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of hospital-acquired infections
      • 3.2.1.2 Advancements in medical technology and drug development
      • 3.2.1.3 Growing focus on patient safety and quality care
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of patient awareness and diagnostics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Reimbursement scenario
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Pipeline analysis
  • 3.10 Future market trends
  • 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antibacterial drugs
  • 5.3 Antiviral drugs
  • 5.4 Antifungal drugs
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Intravenous (IV)
  • 6.3 Oral
  • 6.4 Topical
  • 6.5 Inhalation

Chapter 7 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Surgical site infections
  • 7.3 Bloodstream infections
  • 7.4 Urinary tract infections
  • 7.5 Ventilator-associated pneumonia
  • 7.6 Other hospital infections

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 AbbVie
  • 9.3 Allergan
  • 9.4 Eugia Pharma
  • 9.5 Bayer
  • 9.6 DAIICHI SANKYO COMPANY
  • 9.7 F. Hoffmann-La Roche
  • 9.8 Glenmark Pharmaceuticals
  • 9.9 GSK
  • 9.10 Hikma Pharmaceuticals
  • 9.11 Melinta Therapeutics
  • 9.12 Merck & Co
  • 9.13 Pfizer
  • 9.14 Sanofi
  • 9.15 Viatris